# Insights by Shea Hoffman

Writing on audience selection, positioning, customer trust, acquisition economics, telehealth, and the research-use-only peptide market.

These essays are personal analysis informed by founder and operator conversations. They are not medical or legal advice.

## Published essays

- [Peptide marketing agency or generalist? Compare the operating model](https://sheahoffman.work/insights/peptide-marketing-agency-vs-generalist.md) — 2026-09-22. A peptide specialist is not automatically the better agency. Compare how each team handles positioning, constraints, continuity, conversion, and business economics.
- [Should a cash-pay telehealth company hire an agency or build in-house?](https://sheahoffman.work/insights/telehealth-marketing-agency-vs-in-house.md) — 2026-09-22. A telehealth marketing agency can add range and speed. An internal team can own the learning. The right answer depends on what the business has already proved.
- [The next telehealth wedge may be the form factor](https://sheahoffman.work/insights/telehealth-form-factor-positioning.md) — 2026-09-17. Strips, tablets, lozenges, pouches, gummies and sprays can create a reason to notice. The format still has to survive the clinical and commercial questions.
- [Comparison content cannot create your peptide company’s position](https://sheahoffman.work/insights/comparison-content-cannot-create-positioning.md) — 2026-09-14. Comparison pages can capture demand. They cannot give an interchangeable peptide business a reason to be chosen.
- [Your customers trust you. Will they follow you into telehealth?](https://sheahoffman.work/insights/customers-follow-into-telehealth.md) — 2026-09-14. An existing wellness audience gives you a place to start. It does not tell you what that audience believes you are for.
- [The peptide gold rush needs an exit plan](https://sheahoffman.work/insights/peptide-gold-rush-exit-plan.md) — 2026-09-14. Traffic around a hot catalog can build a business. It is not the same thing as building a business that can survive the market changing.
- [Ask your agency what happens when something breaks](https://sheahoffman.work/insights/restricted-category-agency-continuity.md) — 2026-09-14. In a restricted category, launch capability matters. Clear ownership, measurement, and recovery discipline matter more over time.
- [Looking legitimate is not the same as earning trust](https://sheahoffman.work/insights/ruo-peptide-trust-is-operational.md) — 2026-09-14. In the RUO peptide market, a polished identity can open the door. Operational evidence determines whether trust survives scrutiny.
- [Telehealth founders keep budgeting for media before earning a position](https://sheahoffman.work/insights/telehealth-acquisition-needs-a-position.md) — 2026-09-14. High CPMs are painful. Paying them before deciding exactly who the business is for is worse.
- [Ask who controls the patient relationship before choosing a telehealth platform](https://sheahoffman.work/insights/telehealth-platform-patient-relationship.md) — 2026-09-14. Clinical infrastructure affects patient continuity, data access, acquisition, and enterprise value. Ask how separation works before signing.
- [Your peptide catalog isn’t a positioning strategy](https://sheahoffman.work/insights/peptide-catalog-positioning.md) — 2026-09-10. Large peptide catalogs create inventory, not a reason to choose. Positioning starts with a specific audience and changes how the business operates.